MAIA Biotechnology (MAIA)

• Market cap: $55.4M
• 1 day: -1.18%
• 5 days: 8.39%
• 1 month: 7.01%
• 3 months: -4%
• 6 months: 5%
• Year to date: -19.62%
• 1 year: -48.31%
• 5 years: -62.33%
• 10 years: -62.33%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Employees: 13

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

75% more capital invested

Capital invested by funds: $2.26M [Q1] → $3.95M (+$1.69M) [Q2]

2.54% more ownership

Funds ownership: 4.99% [Q1] → 7.53% (+2.54%) [Q2]

0% more funds holding

Funds holding: 20 [Q1] → 20 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4